Bevacizumab

Generic Name: Bevacizumab

Brand Names: Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi

Drug Type: Biotech

Chemical Formula: -

CAS Number: 216974-75-3

Unique Ingredient Identifier: 2S9ZZM9Q9V

Background: There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...

Indication: As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...

Associated Conditions: Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Associated Therapies: First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment

Clinical Trials

Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants with a KRAS or NRAS Mutation

Phase 2

Recruiting

Conditions: CRC
Metastatic Colorectal Cancer
KRAS/NRAS Mutation

Interventions: Drug: Onvansertib
Drug: FOLFIRI
Drug: Bevacizumab
Drug: FOLFOX

First Posted Date: 2023-10-30

Last Posted Date: 2024-12-06

Lead Sponsor: Cardiff Oncology

Target Recruit Count: 90

Registration Number: NCT06106308

Locations: 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
Mayo Clinic - Arizona, Phoenix, Arizona, United States

and more 38 locations

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

Phase 2

Recruiting

Conditions: Unresectable Metastatic Colorectal Cancer

Interventions: Drug: ABBV-400
Drug: Bevacizumab
Drug: Folinic Acid
Drug: Fluorouracil
Drug: Irinotecan

First Posted Date: 2023-10-30

Last Posted Date: 2024-12-17

Lead Sponsor: AbbVie

Target Recruit Count: 206

Registration Number: NCT06107413

Locations: 🇧🇪
Universitair Ziekenhuis Leuven /ID# 257079, Leuven, Vlaams-Brabant, Belgium
🇺🇸
Highlands Oncology Group, PA /ID# 259424, Springdale, Arkansas, United States
🇺🇸
City of Hope National Medical Center /ID# 257576, Duarte, California, United States

and more 32 locations

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2023-10-24

Last Posted Date: 2024-08-28

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 120

Registration Number: NCT06096779

Locations: 🇺🇸
University of Southern California; Oncology/Hematology, Newport Beach, California, United States
🇺🇸
Veterans Affairs Pittsburgh Healthcare System - NAVREF - PPDS, Pittsburgh, Pennsylvania, United States
🇺🇸
Kelsey Research Foundation, Houston, Texas, United States

and more 40 locations

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Phase 2

Recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Pembrolizumab
Drug: Bevacizumab
Drug: Cyclophosphamide

First Posted Date: 2023-10-16

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT06083844

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Phase 2

Not yet recruiting

Conditions: Fallopian-tube Cancer
Ovarian Cancer
High Grade Serous Adenocarcinoma of Ovary
High Grade Endometrioid Ovarian Cancer
Primary Peritoneal Cancer

Interventions: Drug: Fluzoparib Capsules
Drug: Bevacizumab

First Posted Date: 2023-10-02

Last Posted Date: 2023-10-02

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 44

Registration Number: NCT06063070

Locations: 🇨🇳
Sun Yat-sen University Cancer Cetntre, Guangzhou, Guangdong, China

Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.

Phase 2

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Envafolimab
Drug: Trifluridine/Tipiracil
Drug: Bevacizumab

First Posted Date: 2023-09-29

Last Posted Date: 2023-10-11

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 33

Registration Number: NCT06060704

Locations: 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

Phase 2

Recruiting

Conditions: Glioblastoma

Interventions: Drug: Bevacizumab
Drug: PD-L1 t-haNK
Drug: N-803

First Posted Date: 2023-09-29

Last Posted Date: 2024-08-19

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 20

Registration Number: NCT06061809

Locations: 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

Safety and Efficacy of NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Phase 1

Recruiting

Conditions: Glioblastoma, IDH-wildtype
Head and Neck Squamous Cell Carcinoma
Melanoma
Merkel Cell Carcinoma
Mismatch Repair Deficient Solid Malignant Tumor
Microsatellite Instability-High Colorectal Cancer
Colorectal Cancer
Microsatellite Instability-High Solid Malignant Tumor
Non-small Cell Lung Cancer
Renal Cell Carcinoma

Interventions: Drug: NEO212 Oral Capsule
Drug: FOLFIRI Protocol
Drug: Ipilimumab
Drug: Regorafenib
Drug: Pembrolizumab
Drug: Carboplatin
Drug: Paclitaxel
Drug: Bevacizumab
Drug: Nivolumab

First Posted Date: 2023-09-21

Last Posted Date: 2024-10-16

Lead Sponsor: Neonc Technologies, Inc.

Target Recruit Count: 134

Registration Number: NCT06047379

Locations: 🇺🇸
Precision NextGen Oncology, Beverly Hills, California, United States
🇺🇸
Northwest Medical Specialties, Tacoma, Washington, United States